Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Stock Report

| More

Suven Life Sciences announces Top-Line Results of SUVN-502 (Masupirdine) Phase 2A Study in Patients with Moderate Alzheimer's Disease (AD)

Posted On: 2019-11-30 16:58:51

SUVN-502 did not meet the pre-specified primary endpoint

Meaningful improvements and potential beneficial effects on cognitive function, behavioral and neuropsychiatric end points were emerged based on subgroup analyses.

SUVN-502 was safe and well tolerated with no significant adverse events

Suven Life Sciences announces top-line results from its Phase 2A proof of concept study evaluating the efficacy, safety and tolerability of Masupirdine (SUVN-502). The first of its kind trial which focused on advanced stage AD patients (moderate AD) who are currently treated with standard of care Donepezil and Memantine. The unique triple-therapy (Masupirdine+ Donepezil+ Memantine) design was based on efficacy results in pre-clinical cognition models in which masupirdine enhances the effects of combined treatment with Donepezil and Memantine.

The primary efficacy endpoint of the trial is change from baseline to Week 26 in ADAS-Cog 11 score. The secondary outcome measures are MMSE, CDR-SB, ADCS-ADL, NPI, C-SDD, safety and tolerability assessment.

Findings of this Phase 2A study:

- Masupirdine (SUVN-502) is safe and well tolerated without significant adverse events.

- Triple therapy of Masupirdine (SUVN-502) with Donepezil and Memantine proof of concept phase 2 study missed its pre-specified primary endpoint.

- Subgroup analyses on cognition, function, behavioral, neuropsychiatric inventory and secondary endpoints revealed interesting, statistically significant and potentially beneficial data sets.

- Potential beneficial effects and statistically significant results with Masupirdine treated groups on cognition emerged upon considering combinations of Patients Age, Memantine regimen, Memantine plasma concentration, Memantine treatment duration and Alzheimer's disease duration.

- Sub-population of Masupirdine treated patients showed significant improvement and statistically significant reduction in the behavioral symptoms in the domains of agitation / aggression and delusions /hallucination as assessed by the NPI subscale scores.

- Detailed study outcomes of the above findings will be presented through one oral and six poster presentations at Clinical Trials on Alzheimer's Disease (CTAD) being held at San Diego from 4th - 7th December 2019.

We are very disappointed with the outcome of this trial but the findings present an important step forward in further exploration of the potential therapeutic effects of Masupirdine (SUVN-502) in Alzheimer's Disease (AD) and Behavioral & Psychological Symptoms in Dementia (BPSD). We will work with regulators and potential partnering companies in the design and conduct of future studies for further exploration of the potential of Masupirdine (SUVN-502) says Venkat Jasti, CEO of Suven.

Shares of SUVEN LIFE SCIENCES LTD. was last trading in BSE at Rs.314.05 as compared to the previous close of Rs. 312.75. The total number of shares traded during the day was 52597 in over 1718 trades.

The stock hit an intraday high of Rs. 317.6 and intraday low of 309.85. The net turnover during the day was Rs. 16529894.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

Control Print Ltd board approves interim dividend of Rs.3.5 for 2019-20

TVS Motor Company forays into electric mobility with connected and advanced technology scooter 'TVS iQube Electric'

PSP Projects Limited receives work orders of Rs. 357.90 crores

Prabhat Technologies India Ltd updates on inadvertent trading done in shares of promoter

Control Print Ltd consolidated Q3 net profit higher at Rs. 8.81 crore

Chemcrux Enterprises Limited receives award at 4th IPF Industrial Excellence Awards

Pondy Oxides & Chemicals Ltd reports QoQ jump in PAT

DCB Bank Ltd Q3 net profit climbs to Rs. 96.70 crore

CRISIL updates on rating of Jindal Drilling Industries Ltd

SKP Securities Ltd consolidated net profit at Rs. 0.05 crore in Q3

Muthoot Capital Services Ltd Q3 net profit up QoQ to Rs. 18.95 crore

APL Apollo Tubes Ltd consolidated Q3 FY20 net profit surges to Rs. 74.26 crore

Siyaram Silk Mills Ltd consolidated Q3 net profit slides to Rs. 7.63 crore

Indo Cotspin Ltd Q3 net profit at Rs. 0.0334 crore

ICICI Bank Ltd reports consolidated PAT at Rs. 4670.10 crores

Muller & Phipps India Ltd Q3 net profit at Rs. 0.03 crore

Bhageria Industries Ltd posts PAT of Rs. 17.74 crores in Q3

Maruti Suzuki NEXA rolls out Stylish and Sporty Ciaz S

Cybele Industries Ltd Q3 loss at Rs. 0.90 crore

IndiGo launches direct connection between Delhi and Bangkok

mBAJA & eBAJA Design and Technical Evaluation and Dynamic Events held today for BAJA SAEINDIA 2020

Wendt India Ltd announces Q3, 9MFY20 results

ABM Knowledgeware Ltd Q3 consolidated net profit slips to Rs. 3.08 crore

Prestige Estates Projects Ltd consolidated Q3 net profit climbs to Rs. 161.8 crore

EIH Ltd Q3 net profit higher QoQ, YoY

Bank of Baroda reports loss in Q3 FY2020

Eldeco Housing and Industries Ltd announces Q3, 9MFY20 results

BEML CMD gets Most Admired Leader Award

Siemens Ltd to acquire 99.22% in C&S Electric Ltd for Rs. 2100 crore

VST Tillers Tractors Ltd enters into MOU with Zetor Tractors

NHPC declared successful resolution applicant for Jalpower Corporation Ltd

L&T raises Rs. 1000 crore through 6.72% NCDs

Solapur Tollways Pvt Ltd receives completion certificate for part of NH-9 project

Cipla gets 4 observations from USFDA for API facility at Bommasandra, Bangalore

ALLSEC Technologies Ltd consolidated Q3 FY20 net profit at Rs. 8.55 crore

Wendt India Ltd Q3 consolidated PAT falls to Rs. 2.20 crore

Faze Three Autofab Ltd Q3 net profit at Rs. 0.48 crore

Emkay Global Financial Services Ltd Q3 loss at Rs. 1.41 crore

ION Exchange India Ltd consolidated Q3 PAT higher at Rs. 26.31 crore

Shree Bhavya Fabrics Ltd posts net profit of Rs. 0.77 crore in Q3

Mangalam Drugs & Organics Ltd Q3 PAT jumps to Rs. 1.65 crore

ARO Granite Industries Ltd Q3 net profit at Rs. 0.65 crore

JSW Steel Ltd consolidated Q3 PAT declines to Rs. 211 crores

Udaipur Cement Works Ltd posts PAT of Rs. 0.97 crore in Q3

Strides announces successful completion of US FDA inspection at its Alathur facility with Zero 483 observations

Sonata Software Ltd reports Rs.75.86 crores net profit in Q3 FY20

Oriental Hotels Ltd posts consolidated PAT of Rs. 7.31 crore

Kirloskar Ferrous Industries Ltd Q3 PAT increases QoQ to Rs. 23.33 crore

Indian Bank reports Q3 net profit of Rs. 247.16 crore

Sunil Agro Foods Ltd posts net profit of Rs. 0.14 crore in Q3







Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019